Actas dermo-sifiliograficas最新文献

英文中文

Dissecting Cellulitis Associated With Hormone Therapy in a Transgender Man 一名跨性别男性的夹层蜂窝织炎与激素治疗相关。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-13 DOI: 10.1016/j.ad.2025.104555

J.L. Rodrigues Machado , M. Domingos Almeida , R.F. Cortez de Almeida , D. Fernandes Melo

引用次数: 0

Clinical Lessons in Dermatology: Insights into Diagnosis, Management, and Professional Practice 皮肤病学临床课程：诊断、管理和专业实践的见解。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-13 DOI: 10.1016/j.ad.2025.104554

J.R. Estela Cubells , W.D. James

引用次数: 0

Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain 杜匹单抗治疗特应性皮炎的长期持久性、安全性和有效性：一项来自西班牙的真实世界回顾性多中心研究

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-13 DOI: 10.1016/j.ad.2025.104563

J.F. Silvestre-Salvador , S. Santos-Alarcón , A. Mengual-Sendra , V. Zaragoza-Ninet , M.P. Ortega-García , M. Rodriguez , E. Monte-Boquet , R.F. Ruiz de Apodaca , N. Pérez Prior , F.J. Miquel-Miquel , J. Borras-Blasco

Background

The safety and efficacy profile of dupilumab in the management of atopic dermatitis (AD) are established in clinical trials. However, long-term real-world persistence data in Spain are limited.

Objective

The primary endpoint of the study was to assess the 4-year persistence of dupilumab in routine clinical practice in patients with moderate-to-severe AD. Secondary endpoints included the analysis of safety and efficacy profile during the same period of time.

Methods

We conducted a retrospective cohort study of dispensation registries and health records from 5 hospitals. Adults with moderate-to-severe AD starting on dupilumab treatment were followed for 4-years. Dupilumab persistence was estimated using Kaplan–Meier analysis. Efficacy was measured by changes in EASI and IGA scores. Significant adverse events (AEs) leading to discontinuation were recorded.

Results

A total of 251 patients included (mean age, 46 years; 59.4%, men; 64.5% with at least 1 atopic comorbidity; mean time from AD diagnosis, 14.5 years). Of these, 196 (78.1%) had been on ≥2 systemic therapies before starting dupilumab. Baseline EASI and IGA values averaged 27.9 and 4.0, respectively. Persistence rates were 90%, 80%, 78%, and 73% after 1, 2, 3, and 4-years, respectively. By 16 weeks, 47.8% and 54.7% of patients achieved EASI ≤3 or IGA ≤1, increasing to 76.3% and 77.2% by 52 weeks, and reaching 90.9% in the group followed for >3 years. A total of 38 patients (13.5%) discontinued dupilumab, mainly due to inefficacy (5.6%) and AEs (1.2%).

Conclusion

Dupilumab effectively reduced AD severity within the first few weeks, with most patients achieving mild/minimal disease activity or complete clearance by year 1. The observed safety profile was consistent with known data. High persistence rates up to 4-years suggest satisfaction with dupilumab long-term safety and efficacy profile in managing moderate-to-severe AD.

背景：杜匹单抗治疗特应性皮炎（AD）的安全性和有效性已经在临床试验中得到证实。然而，西班牙的长期实际持久性数据是有限的。目的：该研究的主要终点是评估dupilumab在中重度AD患者常规临床实践中的4年持续性。次要终点包括同一时期的安全性和有效性分析。方法：我们对5家医院的配药登记和健康记录进行了回顾性队列研究。接受dupilumab治疗的中度至重度AD成人患者随访4年。使用Kaplan-Meier分析估计Dupilumab的持久性。通过EASI和IGA评分的变化来衡量疗效。记录导致停药的重大不良事件（ae）。结果：共纳入251例患者（平均年龄46岁；男性占59.4%；64.5%至少有1种特应性合并症；从AD诊断到平均时间为14.5年）。其中，196例（78.1%）患者在开始dupilumab治疗前接受过2次以上的全身治疗。基线EASI和IGA值平均分别为27.9和4.0。1年、2年、3年和4年后的持续率分别为90%、80%、78%和73%。16周时，EASI≤3或IGA≤1的患者比例分别为47.8%和54.7%，52周时分别为76.3%和77.2%，随访3年组达到90.9%。共有38名患者（13.5%）停药，主要是由于无效（5.6%）和不良事件（1.2%）。结论：Dupilumab在最初几周内有效降低了AD的严重程度，大多数患者在第1年达到轻度/最小疾病活动或完全清除。观察到的安全性与已知数据一致。长达4年的高持续率表明dupilumab在治疗中重度AD方面的长期安全性和有效性令人满意。

{"title":"Long-term Persistence, Safety and Efficacy Profile of Dupilumab in Atopic Dermatitis: A Real-world Retrospective Multicenter Study From Spain","authors":"J.F. Silvestre-Salvador , S. Santos-Alarcón , A. Mengual-Sendra , V. Zaragoza-Ninet , M.P. Ortega-García , M. Rodriguez , E. Monte-Boquet , R.F. Ruiz de Apodaca , N. Pérez Prior , F.J. Miquel-Miquel , J. Borras-Blasco","doi":"10.1016/j.ad.2025.104563","DOIUrl":"10.1016/j.ad.2025.104563","url":null,"abstract":"<div><h3>Background</h3><div>The safety and efficacy profile of dupilumab in the management of atopic dermatitis (AD) are established in clinical trials. However, long-term real-world persistence data in Spain are limited.</div></div><div><h3>Objective</h3><div>The primary endpoint of the study was to assess the 4-year persistence of dupilumab in routine clinical practice in patients with moderate-to-severe AD. Secondary endpoints included the analysis of safety and efficacy profile during the same period of time.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of dispensation registries and health records from 5 hospitals. Adults with moderate-to-severe AD starting on dupilumab treatment were followed for 4-years. Dupilumab persistence was estimated using Kaplan–Meier analysis. Efficacy was measured by changes in EASI and IGA scores. Significant adverse events (AEs) leading to discontinuation were recorded.</div></div><div><h3>Results</h3><div>A total of 251 patients included (mean age, 46 years; 59.4%, men; 64.5% with at least 1 atopic comorbidity; mean time from AD diagnosis, 14.5 years). Of these, 196 (78.1%) had been on ≥2 systemic therapies before starting dupilumab. Baseline EASI and IGA values averaged 27.9 and 4.0, respectively. Persistence rates were 90%, 80%, 78%, and 73% after 1, 2, 3, and 4-years, respectively. By 16 weeks, 47.8% and 54.7% of patients achieved EASI ≤3 or IGA ≤1, increasing to 76.3% and 77.2% by 52 weeks, and reaching 90.9% in the group followed for >3 years. A total of 38 patients (13.5%) discontinued dupilumab, mainly due to inefficacy (5.6%) and AEs (1.2%).</div></div><div><h3>Conclusion</h3><div>Dupilumab effectively reduced AD severity within the first few weeks, with most patients achieving mild/minimal disease activity or complete clearance by year 1. The observed safety profile was consistent with known data. High persistence rates up to 4-years suggest satisfaction with dupilumab long-term safety and efficacy profile in managing moderate-to-severe AD.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104563"},"PeriodicalIF":2.8,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diffuse Eczematous Reaction to Imiquimod 5% Cream 咪喹莫特5%乳膏的弥漫性湿疹反应。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-13 DOI: 10.1016/j.ad.2025.104558

C. Fidanzi, N. Mori, V. Dini, E. Manni

引用次数: 0

Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study 使用Secukinumab治疗化脓性汗腺炎的真实世界经验：来自secure - spain研究的263例患者的多中心回顾性分析

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-13 DOI: 10.1016/j.ad.2025.104562

A. Martorell , E. Vilarrasa-Rull , P. Fernandez-Crehuet , A. Molina-Leyva , M. Mansilla , R. Garcia-Ruiz , P. Garbayo-Salmons , J.M. Ortiz-Salvador , F. Alfageme-Roldan , J. Garcias-Ladaria , J. Bassas-Vila , I. Fuertes-de-Vega , L. Carnero-Gonzalez , M. Almenara-Blasco , I. Torres-Navarro , R. Aguayo-Ortiz , P. Gil Pallares , R. Fornons-Servent , I. Gracia-Darder , V. Mora-Fernández , J. Melgosa

Background/objective

There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS).

Methods

This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300 mg every four weeks) between 2020 and 2024. Eligible patients were aged ≥18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (≥50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a ≥55% reduction in the International HS Severity Score (IHS4-55) and adverse events.

Results

A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8 ± 13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7 ± 10.0 at baseline to 7.6 ± 5.6 at week 24 (p < 0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events.

Conclusions

Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.

背景/目的：由于III期试验的结果与临床实践研究报告的结果不同，对secukinumab的缓解率尚无共识。本研究旨在评估secukinumab在中重度化脓性汗腺炎（HS）患者中的中期安全性和有效性。方法：这项回顾性、多中心研究纳入了2020年至2024年间接受secukinumab（每4周300 mg）治疗的中重度HS患者。符合条件的患者年龄≥18岁，临床诊断为中重度HS，至少随访24周。关键排除包括使用非标准secukinumab给药方案治疗的患者或临床数据不足的患者。主要终点是在第16周和第24周达到HiSCR50（结节和脓肿总数减少≥50%）。次要终点包括国际HS严重程度评分（IHS4-55）和不良事件降低≥55%。结果：共纳入263例患者（女性49.4%，男性50.6%，平均年龄41.8±13.2岁）。最常见的HS表型为混合型（49.4%），55.1%为Hurley III期疾病。在第16周和第24周，分别有57.4%和63.6%的患者达到HiSCR50。平均IHS4评分从基线时的16.7±10.0降至第24周时的7.6±5.6 （p < 0.0001）。在第16周和第24周，52%和56%的患者达到了IHS4-55反应。14.5%的患者因缺乏疗效或不良事件而停止使用Secukinumab。结论：在现实环境中，Secukinumab对中度至重度患者具有显著的安全性和有效性，其结果优于早期临床试验报告。由于治疗效果的差异，第16周和第24周的反应评估至关重要。

{"title":"Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study","authors":"A. Martorell , E. Vilarrasa-Rull , P. Fernandez-Crehuet , A. Molina-Leyva , M. Mansilla , R. Garcia-Ruiz , P. Garbayo-Salmons , J.M. Ortiz-Salvador , F. Alfageme-Roldan , J. Garcias-Ladaria , J. Bassas-Vila , I. Fuertes-de-Vega , L. Carnero-Gonzalez , M. Almenara-Blasco , I. Torres-Navarro , R. Aguayo-Ortiz , P. Gil Pallares , R. Fornons-Servent , I. Gracia-Darder , V. Mora-Fernández , J. Melgosa","doi":"10.1016/j.ad.2025.104562","DOIUrl":"10.1016/j.ad.2025.104562","url":null,"abstract":"<div><h3>Background/objective</h3><div>There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS).</div></div><div><h3>Methods</h3><div>This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300mg every four weeks) between 2020 and 2024. Eligible patients were aged ≥18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (≥50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a ≥55% reduction in the International HS Severity Score (IHS4-55) and adverse events.</div></div><div><h3>Results</h3><div>A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8±13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7±10.0 at baseline to 7.6±5.6 at week 24 (<em>p</em>  <!-->0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events.</div></div><div><h3>Conclusions</h3><div>Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104562"},"PeriodicalIF":2.8,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Backhaus Towel Clamps: A Noble Ally in the Operating Room Backhaus毛巾夹：手术室的高贵盟友。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-12 DOI: 10.1016/j.ad.2025.104559

A. Bennassar Vicens

引用次数: 0

Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis 口服罗氟司特长期治疗行为障碍：一项多中心观察分析。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-12 DOI: 10.1016/j.ad.2025.104561

R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel

Background

Recurrent aphthous stomatitis (RAS) and Behçet's disease (BD) are part of the Behçet spectrum disorders (BSD), sharing genetic traits and characterized by recurrent ulcers. No systemic treatment is approved for RAS or incomplete BD, despite significant quality-of-life impacts.

Objective

To evaluate the efficacy of roflumilast, a PDE4 inhibitor, in BSD patients and compare responses between RAS and BD.

Methods

This analytical observational study included a total of 33 patients with BSD (22, RAS; 11, BD) from 5 Spanish centers, followed over 52 weeks. Data were collected retrospectively and prospectively, assessing flare-ups, ulcers, pain, and duration. Statistical models compared outcomes across treatment periods.

Results

Roflumilast significantly reduced all studied response variables, with no loss of long-term efficacy. Differences between RAS and BD were minimal and clinically irrelevant. Adverse events occurred in 63% of patients, mostly mild and self-limiting, with tolerability improved through dose adjustments. Two patients (6.25%) dropped out due to adverse events.

Conclusion

Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.

背景：复发性口疮性口炎（RAS）和behet病（BD）是behet谱系障碍（BSD）的一部分，具有相同的遗传特征，并以复发性溃疡为特征。尽管RAS或不完全性双相障碍对生活质量有显著影响，但尚未批准系统性治疗。目的：评价PDE4抑制剂罗氟米司特治疗BSD患者的疗效，并比较RAS和BSD的疗效。方法：本分析性观察性研究包括来自西班牙5个中心的33例BSD患者（22例RAS， 11例BD），随访52周。回顾性和前瞻性收集数据，评估急性发作、溃疡、疼痛和持续时间。统计模型比较了不同治疗期的结果。结果：罗氟司特显著降低了所有研究的反应变量，没有丧失长期疗效。RAS和BD之间的差异很小，与临床无关。63%的患者发生了不良事件，大多是轻度和自限性的，通过剂量调整可改善耐受性。2例患者（6.25%）因不良事件退出。结论：罗氟司特治疗BSD有效，为解决RAS和BD未满足的需求提供了一种安全的选择，其良好的安全性和长期疗效支持其在常规临床实践中的应用。

{"title":"Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis","authors":"R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel","doi":"10.1016/j.ad.2025.104561","DOIUrl":"10.1016/j.ad.2025.104561","url":null,"abstract":"<div><h3>Background</h3><div>Recurrent aphthous stomatitis (RAS) and Behçet's disease (BD) are part of the Behçet spectrum disorders (BSD), sharing genetic traits and characterized by recurrent ulcers. No systemic treatment is approved for RAS or incomplete BD, despite significant quality-of-life impacts.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy of roflumilast, a PDE4 inhibitor, in BSD patients and compare responses between RAS and BD.</div></div><div><h3>Methods</h3><div>This analytical observational study included a total of 33 patients with BSD (22, RAS; 11, BD) from 5 Spanish centers, followed over 52 weeks. Data were collected retrospectively and prospectively, assessing flare-ups, ulcers, pain, and duration. Statistical models compared outcomes across treatment periods.</div></div><div><h3>Results</h3><div>Roflumilast significantly reduced all studied response variables, with no loss of long-term efficacy. Differences between RAS and BD were minimal and clinically irrelevant. Adverse events occurred in 63% of patients, mostly mild and self-limiting, with tolerability improved through dose adjustments. Two patients (6.25%) dropped out due to adverse events.</div></div><div><h3>Conclusion</h3><div>Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104561"},"PeriodicalIF":2.8,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milia-Like Papules and Ulcerated Nodules in a Man With Bartter Syndrome 巴特综合征患者的粟粒样丘疹和溃疡性结节。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-12 DOI: 10.1016/j.ad.2025.104557

E. Carmona-Rocha , E. Subiela , L. Puig , C.E. Morales-Munera

引用次数: 0

Use of an Alar Cartilage Chondromucosal Graft for Posterior Lamella Reconstruction in Full-Thickness Lower Eyelid Defects 鼻翼软骨软骨黏膜移植在下眼睑全层缺损后板瓣重建中的应用。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-11 DOI: 10.1016/j.ad.2025.104542

E. Samaniego González , E. Pérez Díez , M. Cuesta Lasso , M. Criado Otero

引用次数: 0

Survey of Usual Clinical Practice in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab Regarding the Management of Antihistamines 奥玛珠单抗治疗慢性自发性荨麻疹患者抗组胺药管理的临床调查

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-11 DOI: 10.1016/j.ad.2025.104549

E. Gómez de la Fuente , F.J. Ortiz de Frutos , M. Bergón Sendín , G. Melé Ninot

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Actas dermo-sifiliograficas

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀